



BEST OF ASCO[®]

OFFICIALLY LICENSED

2025 ANNUAL MEETING

27 JUN

PROGRAMA

ORGANIZAÇÃO



BEST OF ASCO[®]

OFFICIALLY LICENSED

2025 ANNUAL MEETING

MENSAGEM DA SOCIEDADE PORTUGUESA DE ONCOLOGIA (SPO)

A SPO realiza pela terceira vez, no nosso país, o **BEST OF ASCO**, sob a chancela da **ASCO**. Este evento contará com a participação de Especialistas que apresentarão os 50 estudos mais recentes e inovadores da conferência anual da Sociedade Americana de Oncologia Clínica, com foco na aplicação para a prática clínica.

Porque a qualidade da reunião depende da participação de todos, convidamos a estarem connosco neste dia!

COMISSÃO ORGANIZADORA

José Luís Passos Coelho

Presidente da SPO

Hospital da Luz Lisboa

Renato Cunha

ULSTMAD

Pedro Simões

ULS Loures-Odivelas

COMISSÃO CIENTÍFICA

Nuno Bonito

Presidente-Eleito da SPO

IPO de Coimbra

Cláudia Caeiro

Hospital CUF Porto

Inês Nobre Góis

ULS de Coimbra

Joana Rodrigues

ULS de Coimbra

Leonor Ribeiro

ULS de Santa Maria

Margarida Brito

IPO de Lisboa

Marta Pinto

ULS de Viseu Dão-Lafões

Pedro Madeira

IPO de Coimbra

Ricardo Veiga

Hospital da Luz Lisboa

Sara Alves

IPO do Porto

MAMA

Berta Sousa, Fundação Champalimaud
Ana Ferreira, IPO do Porto
Inês Eiriz, ULS Amadora/Sintra

PULMÃO

Maria Cassiano, IPO Porto
Paula Fidalgo, ULS de Santo António

SURVIVORSHIP

Andreia Capela, ULS Gaia/Espinho
Michael Luís, IPO do Porto

BIOLOGIA/IMUNOTERAPIA

Teresa Amaral, Skin Cancer Center – Tuebingen
Ana Rodrigues, IPO do Porto

GINECOLÓGICOS

Marta Ferreira, IPO do Porto
Júlia Arede, ULS Região de Leiria

SNC

Teresa Pacheco, ULS de Santa Maria
Raquel Fontes, ULS de Braga

PELE

Dânia Marques, IPO do Porto
Patrícia Pereira, IPO de Lisboa

CABEÇA E PESCOÇO

Leonor Pinto, ULS de Coimbra
Inês Leão, ULS de Santa Maria

DIGESTIVOS

Ana Pissarra, Hospital Lusíadas Lisboa
Teresa Fraga, IPO de Coimbra

UROLÓGICOS

Marta Pinto, ULS Viseu Dão-Lafões
Daniela Macedo, Hospital Lusíadas Lisboa

AGENDA

CIENTÍFICA

SALA A

08:30 - 09:00

SESSÃO DE ABERTURA

09:00 - 10:15

MAMA
SESSÃO CONJUNTA

SPO

SPS

Moderadoras: Berta Sousa & Ana Ferreira | **Palestrante:** Inês Eiriz

1003

INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with PIK3CA-mutated, hormone receptor-positive (HR+), HER2-negative (HER2-), endocrine-resistant advanced breast cancer (aBC) (First Author: Nicholas Turner).

LBA1008

Trastuzumab deruxtecan (T-DXd) ± pertuzumab (P) vs taxane + trastuzumab + pertuzumab (THP) for first-line (1L) treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) advanced/metastatic breast cancer (a/mBC): Primary results from DESTINY-Breast09 (First Author: Sara M. Tolaney).

LBA109

Sacituzumab govitecan (SG) + pembrolizumab vs chemotherapy + pembrolizumab in patients with previously untreated PD-L1+ advanced or metastatic triple-negative breast cancer (TNBC): Primary results from the randomized phase 3 ASCENT-04/KEYNOTE-D19 study (First Author: Sara M. Tolaney).

LBA500

De-escalated neoadjuvant taxane plus trastuzumab and pertuzumab with or without carboplatin in HER2-positive early breast cancer (neoCARHP): A multicentre, open-label, randomised, phase 3 trial (First Author: Kun Wang).

LBA4

Camizestrant + CDK4/6 inhibitor (CDK4/6i) for the treatment of emergent ESR1 mutations during first-line (1L) endocrine-based therapy (ET) and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC): Phase 3, double-blind ctDNA-guided SERENA-6 trial (First Author: Nicholas C. Turner).

10:15 - 11:00

SURVIVORSHIP

Moderadora: Andreia Capela | **Palestrante:** Michael Luís

12007

Romiplostim for chemotherapy-induced thrombocytopenia (CIT) in colorectal, gastroesophageal, and pancreatic cancers: A global, phase 3, randomized, placebo-controlled trial (RCT) (First Author: Hanny Al-Samkari).

11003

Randomized trial of a supportive oncology care at home intervention for patients with cancer receiving curative treatment (First Author: Ryan David Nipp).

508

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial (First Author: Fátima Cardoso).

12006

A multicenter, randomized, controlled, open-label trial to determine the optimal duration of steroid therapy for mild pneumonitis associated with immune checkpoint inhibitors (First Author: Daichi Fujimoto).

AGENDA

CIENTÍFICA

SALA A

11:00 - 11:30

INTERVALO

11:30 - 12:30

SIMPÓSIO



11:30 - 11:35

ABERTURA

José Luís Passos Coelho

11:35 - 12:20

Novidades no tratamento do Cancro da Mama Precoce RH+ HER2

Susana Sousa

12:20 - 12:30

Discussão

12:30 - 13:30

GINECOLÓGICOS

Moderadora: Marta Ferreira | **Palestrante:** Júlia Arede

LBA5500

TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR (First Author: Sven Mahner).

LBA5504

Pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer: Final analysis results of the phase 3, randomized, double-blind ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (First Author: Linda R. Duska).

LBA5507

ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72) (First Author: Alexander Olawaiye).

LBA5506

FIRST/ENGOT-OV44: A phase 3 clinical trial of dostarlimab (dost) and niraparib (nira) in first-line (1L) advanced ovarian cancer (aOC) (First Author: Anne-Claire Hardy-Bessard).

13:30 - 14:30

ALMOÇO

AGENDA

CIENTÍFICA

SALA A

14:30 - 15:30

PELE

Moderadora: Dânia Marques | **Palestrante:** Patrícia Pereira

9506

DREAMseq: A phase III trial of treatment sequences in BRAFV600-mutant (m) metastatic melanoma (MM)—Final clinical results (First Author: Michael Atkins).

LBA9507

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013) (First Author: Zeynep Eroglu).

9515

Lifileucel in patients with advanced melanoma: 5-year outcomes of the C-144-01 study (First Author: Theresa Medina).

6001

Phase 3 trial of adjuvant cemiplimab (cemi) versus placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC) (First Author: Danny Rischin).

15:30 - 16:30

DIGESTIVOS

Moderadora: Ana Pissarra | **Palestrante:** Teresa Fraga

LBA5

Event-free survival in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC) (First Author: Yelena Janjigian).

LBA4002

Trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in second-line treatment of patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) unresectable/metastatic gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJA): Primary analysis of the randomized, phase 3 DESTINY-Gastric04 study (First Author: Kohei Shitara).

LBA1

Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502; ATOMIC) (First Author: Frank A. Sinicrope).

LBA3500

First-line encorafenib + cetuximab + mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (BREAKWATER): progression-free survival and updated overall survival analyses (First Author: Elena Elez).

3501

Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) or NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Expanded analyses from CheckMate 8HW (First Author: Heinz-Josef Lenz).

16:30 - 16:45

ENCERRAMENTO

08:30 - 09:00

SESSÃO DE ABERTURA

09:00 - 10:15

PULMÃO

Moderadora: Maria Cassiano | **Palestrante:** Paula Fidalgo

8006

Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial (First Author: Luis G. Paz-Ares).

LBA8000

Overall survival with neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) in patients with resectable NSCLC in CheckMate 816 (First Author: Patrick M. Forde).

LBA8008

Tarlatamab versus standard of care (SOC) chemotherapy as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis (PA) of the phase 3 DeLLphi-304 trial (First Author: Charles M Rudin).

8001

Neoadjuvant (neoadj) osimertinib (osi) ± chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA (First Author: Jamie E. Chaft).

LBA8505

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study (First Author: Shun Lu).

8507

Sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced EGFR-mutated non-small cell lung cancer (NSCLC): Results from the randomized OptiTROP-Lung03 study (First Author: Li Zhang)

10:15 - 11:00

BIOLOGIA/ IMUNOTERAPIA

Moderadora: Teresa Amaral | **Palestrante:** Ana Rodrigues

3002

Phase I study of iza-bren (BL-B01D1), an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic small cell lung cancer (SCLC) (First Author: Yan Huang).

3004

Efficacy and safety of the DLL3/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial (First Author: Jaume Capdevila).

2501

First-in-human phase I/II trial evaluating BNT142, a first-in-class mRNA encoded, bispecific antibody targeting Claudin 6 (CLDN6) and CD3, in patients (pts) with CLDN6-positive advanced solid tumors (First Author: Timothy A. Yap).

BEST OF ASCO®

OFFICIALLY LICENSED

AGENDA

CIENTÍFICA

SALA B

11:00 - 11:30

INTERVALO

11:30 - 12:30

SIMPÓSIO



SALA A

12:30 - 13:30

SNC

Moderadora: Teresa Pacheco | **Palestrante:** Raquel Fontes

2011

Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: A multicenter, phase 3 randomized trial (First Author: Ayal Aizer).

2002

Final clinical and molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion: NCT00626990 (First Author: Martin Van Den Bent).

2039

Initial report of memory avoidance whole brain radiotherapy to treat brain metastases: A prospective phase 2 trial (First Author: Joshua Palmer).

2034

Risk of intracranial hemorrhage with DOACs vs LMWH in patients with cancer associated thrombosis and brain metastases (First Author: Ali Mushtaq).

13:30 - 14:30

ALMOÇO

14:30 - 15:30

CABEÇA E PESCOÇO

Moderadora: Leonor Pinto | **Palestrante:** Inês Leão

6012

Neoadjuvant and adjuvant pembrolizumab plus standard of care (SOC) in resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC): Exploratory efficacy analyses of the phase 3 KEYNOTE-689 study (First Author: Douglas Adkins).

LBA2

NIVOPOSTOP (GORTEC 2018-01): A phase III randomized trial of adjuvant nivolumab added to radio-chemotherapy in patients with resected head and neck squamous cell carcinoma at high risk of relapse (First Author: Jean Bourhis).

LBA6003

PD-1 blockade with toripalimab incorporated into induction chemotherapy and radiotherapy with or without concurrent cisplatin in locoregionally advanced nasopharyngeal carcinoma (DIAMOND): A multicenter, non-inferiority, phase 3, randomized controlled trial (First Author: Jun Ma).

6013

Long-term results of the randomized, phase 3 KEYNOTE-412 trial of pembrolizumab (pembro) or placebo (pbo) plus concurrent chemoradiotherapy (CRT) for unresected, locally advanced head and neck squamous cell carcinoma (LA HNSCC) (First Author: Yungan Tao).

15:30 - 16:30

UROLÓGICOS

Moderadora: Marta Pinto | **Palestrante:** Daniela Macedo

LBA5006

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes (First Author: Gerhardt Attard).

5001

Multimodal artificial intelligence (MMAI) model to identify benefit from 2nd-generation androgen receptor pathway inhibitors (ARPI) in high-risk non-metastatic prostate cancer patients from STAMPEDE (First Author: Nicholas David James).

4500

Nivolumab plus ipilimumab (NIVO+IPI) vs gemcitabine-carboplatin (gem-carbo) chemotherapy for previously untreated unresectable or metastatic urothelial carcinoma (mUC): Final results for cisplatin-ineligible patients from the CheckMate 901 trial (First Author: Michiel Simon Van Der Heijden).

4503

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA (First Author: Thomas Powles).

4505 & 4514

Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial (First Author: Toni K. Choueiri) & Five-year follow-up results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab (pembro) for the treatment of clear cell renal cell carcinoma (ccRCC) (First Author: Naomi Balzer Haas).

16:30 - 16:45

ENCERRAMENTO

MAJOR SPONSOR



OFFICIAL SPONSORS



PARCEIRO CIENTÍFICO



BEST OF ASCO®
OFFICIALLY LICENSED

